

## Correction

# **Correction: Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]**

Trevor Powles<sup>1</sup>, Alexander Paterson<sup>2</sup>, Eugene McCloskey<sup>3</sup>, Phil Schein<sup>4</sup>, Bobbi Scheffler<sup>5</sup>, Alwynne Tidy<sup>6</sup>, Sue Ashley<sup>6</sup>, Ian Smith<sup>6</sup>, Lars Ottestad<sup>7</sup> and John Kanis<sup>3</sup>

<sup>1</sup>Parkside Oncology, London, UK

<sup>2</sup>Tom Baker Cancer Centre, Calgary, Alberta, Canada

<sup>3</sup>WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK

<sup>4</sup>Department of Clinical Pharmacology, University of Oxford, Oxford, UK

<sup>5</sup>Scheffler Group, Villanova, Pennsylvania, USA

<sup>6</sup>Royal Marsden Hospital, London, UK

<sup>7</sup>Radium Institute, Oslo, Norway

Corresponding author: Trevor Powles, [hdummer@parkside-hospital.co.uk](mailto:hdummer@parkside-hospital.co.uk)

Published: 3 May 2006

This article is online at <http://breast-cancer-research.com/content/8/3/406>

© 2006 BioMed Central Ltd

*Breast Cancer Research* 2006, **8**:406 (doi:10.1186/bcr1413)

It has been brought to our attention that there was a typographical error in our recent article [1] published in March 2006.

In the Conclusions section the final sentence should read:

Questions such as the optimal duration of therapy and efficacy in stage I disease remain to be answered.

## References

1. Powles T, Paterson A, McCloskey E, Schein P, Scheffler B, Tidy A, Ashley S, Smith I, Ottestad L, Kanis J: **Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]**. *Breast Cancer Research* 2006, **8**:R13.